Katy Marshall

DocwireNews

The American Society of Clinical Oncology (ASCO) <a href="https://www.docwirenews.com/post/updated-asco-hcc-guideline-offers-new-recommendations-for-patient-care" target="_blank" rel="noopener">recently released updated guidelines</a> on systemic therapy for patients with advanced hepatocellular carcinoma (HCC). ASCO has now published a <a href="https://ascopubs.org/doi/10.1200/OP.24.00189" target="_blank" rel="noopener">companion piece</a> answering common questions from clinicians on the topic.
The guideline update included recommendations for first-, second-, and third-line therapy options, as well as systemic therapy approaches for patients with Child-Pugh class A and B type disease.
ASCO first noted the factors to consider when choosing between atezolizumab plus bevacizumab or durvalumab plus tremelimumab for patients with Child-Pugh Class A advanced HCC. Data from the IMbrave150 study showed a major difference in progression-free survival with atezolizumab plus bevacizumab compared with sorafenib. In the HIMALAYA trial, researchers found a 25% 48-month overall survival rate for durvalumab plus tremelimumab and a prolonged median duration of response of over 22 months. ASCO noted that further research is needed to determine best first-line treatment options.
On the topic of prioritizing options in the second-line setting, ASCO stated that patient factors have the most impact on treatment decisions. As patient factors fluctuate over the course of treatment, clinicians should maximize patient access to recommended treatment options and continue to reassess appropriate treatments.
When considering the role of immune checkpoint inhibitors (ICIs) in the peritransplant setting, ASCO noted that while therapy with ICIs is not routinely recommended, it does not preclude orthotopic liver transplant. Systemic therapy with ICIs is a last resort treatment option in the post-transplant setting, with recent research demonstrating a 30% rate of acute rejection.
ASCO detailed the potential of combined local and systemic therapy options, including the LAUNCH trial, which investigated transarterial chemoembolization (TACE) plus lenvatinib versus lenvatinib alone. They also highlighted the TACTICS trial on TACE plus sorafenib and the EMERALD-1 study on TACE plus durvalumab and bevacizumab.
“We anticipate that results from locoregional systemic therapy studies will contribute to recommendations in the next iteration of this ASCO guideline,” ASCO wrote.

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Andrew Moreno

Study Assesses Prevalence of Thrombotic Events, Impact on Survival in Patients With New Diagnosis of MM

Thrombosis

Emily Menendez

177Lu-edotreotide Improves PFS, OS Over Everolimus for SSTR-Positive GEP-NETs

GEP-NETs

Latest News

New ASCO Guidelines on Systemic Therapy for Advanced HCC

Unresectable HCC

ASCO has issued a companion piece to previously released guidelines addressing commonly asked questions. 

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe